Physician profile
Tasha J Schellenberg
NPI 1912099029
$2,924.05
in general payments reported to CMS, 2019-2025
18 companies · $906 in 2025
The $906 reported for 2025 was more than what 89% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $462 · 2020: $163 · 2021: $203 · 2022: $417 · 2023: $265 · 2024: $507 · 2025: $906.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,679.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,678.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $891.03 | 2019-2025 | Cequa |
| Harrow Eye, LLC | $319.33 | 2024-2025 | Vevye, Triesence |
| Alcon Vision LLC | $209.11 | 2021-2025 | Tryptyr, Simbrinza, Clareon |
| Kala Pharmaceuticals, INC. | $203.82 | 2019-2022 | |
| Dompe US, INC. | $183.31 | 2021-2025 | Oxervate |
| Bausch & Lomb Americas INC. | $126.40 | 2022-2025 | Vyzulta, Miebo, Ic-8 Apthera Iol |
| Tarsus Pharmaceuticals, INC. | $124.99 | 2024-2025 | Xdemvy |
| Abbvie INC. | $120.35 | 2022-2025 | Alphagan P, Lumigan |
| Aerie Pharmaceuticals, INC. | $108.81 | 2019-2021 | |
| Sight Sciences, INC. | $106.48 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $93.07 | 2019-2023 | |
| Oyster Point Pharma, INC. | $84.51 | 2025 | Tyrvaya, Ryzumvi |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $76.54 | 2020-2021 | |
| Shire North American Group INC | $73.21 | 2019 | |
| Rxsight INC | $72.45 | 2022-2024 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Light Adjustable Lens (Lal) |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $56.63 | 2019-2022 | |
| Eyevance Pharmaceuticals LLC | $51.79 | 2019-2022 | |
| Glaukos Corporation | $22.22 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tasha Schellenberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.